The Medicines Control Authority of Zimbabwe announced that it has approved the use of long-acting injectable cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP) for HIV prevention. This follows the WHO recommendation, announced in July 2022, that CAB-LA may be offered to people at substantial risk of HIV acquisition as part of comprehensive HIV prevention approaches. Two large studies showed that CAB-LA injections every 2 months were safe, well-tolerated, and highly effective in reducing the risk of HIV acquisition among men who have sex with men and transgender women and among cisgender…
Read More#BREAKING: Zimbabwe Approves Injectable PrEP for HIV prevention
